Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company that is pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases. The company has treated more than 75 patients to date. ImmixBio's lead cell therapy asset is NXC-201, which is being developed for the treatment of multiple myeloma and AL amyloidosis. The company believes that NXC-201 could be the world's first outpatient CAR-T cell therapy. ImmixBio's lead TSTx asset is IMX-110, which is currently in Phase 1b/2a clinical trials as a monotherapy and in the IMMINENT-01 combination clinical trial with BeiGene's anti-PD-1 antibody tislelizumab. IMX-110 has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA. ImmixBio's subsidiary, Nexcella, Inc., is developing CAR-T NXC-201 for the treatment of multiple myeloma and AL amyloidosis